8-K: Sarepta Exceeds ELEVIDYS Sales Floor, Reports Strong 2025 Revenue

Sarepta Therapeutics announced preliminary Q4 and full-year 2025 net product revenues, exceeding its ELEVIDYS sales floor and reporting a strong cash position.

Summary

• Preliminary total net product revenue reached $369.6 million for the fourth quarter of 2025 and $1.86 billion for the full-year 2025.
• Preliminary ELEVIDYS net product revenue totaled $110.4 million for the fourth quarter of 2025 and $898.7 million for the full-year 2025.
• Preliminary PMO net product revenues were $259.2 million for the fourth quarter of 2025 and $965.6 million for the full-year 2025.
• The company ended 2025 with a preliminary cash, cash equivalents, restricted cash, and investments balance of approximately $953.8 million.
• ELEVIDYS fourth quarter revenue was impacted by the severe year-end flu season and the rescheduling of 6 patient infusions from December 2025 into 2026.
• Sarepta reconfirmed its yearly sales floor for ELEVIDYS at $500.0 million and stated its intention to exceed it, but will not provide more detailed guidance until evaluating 2026 initiatives.

Sentiment

Score: 8

Explanation: The company reported strong full-year revenue figures, significantly exceeding its ELEVIDYS sales floor, and maintained a healthy cash balance. While Q4 ELEVIDYS revenue was impacted by flu season and rescheduled infusions, the overall financial health and future outlook, including pipeline advancement, are positive. The risks associated with ELEVIDYS are standard for gene therapies and well-disclosed.

Positives

• Achieved $1.86 billion in total net product revenue for full-year 2025, demonstrating solid overall performance.
• ELEVIDYS net product revenue for full-year 2025 reached $898.7 million, significantly exceeding the previously set yearly sales floor of $500.0 million.
• The PMO franchise delivered $965.6 million in net product revenue for full-year 2025, described as 'durable revenue'.
• Generated another quarter of positive cash flow, indicating efficient operations.
• Ended 2025 with a strong preliminary cash, cash equivalents, restricted cash, and investments balance of approximately $953.8 million, providing financial strength for future investments.
• Achieved meaningful pipeline progress in 2025, positioning the company for future growth.
• Enters 2026 on a strong financial footing with significant opportunities in approved therapies and the siRNA pipeline.

Negatives

• ELEVIDYS fourth quarter revenue of $110.4 million was negatively impacted by the severe year-end flu season.
• 6 patient ELEVIDYS infusions had to be rescheduled from December 2025 into 2026, affecting Q4 revenue.
• The reported financial results are preliminary and unaudited, subject to adjustment, and actual results could be materially different.

Risks

• Acute serious liver injury, including life-threatening and fatal acute liver failure, has occurred with ELEVIDYS, particularly in patients with preexisting liver impairment.
• ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 of the DMD gene.
• Increased susceptibility to serious infections may occur due to concomitant administration of corticosteroid regimen and additional immunosuppressants with ELEVIDYS.
• Acute, serious, life-threatening myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion.
• Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or after ELEVIDYS administration.
• Immune-mediated myositis, including serious and life-threatening events, has occurred approximately 1 month following ELEVIDYS infusion.
• Preexisting immunity against AAVrh74 may impede transgene expression, and ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers ≥ 1:400.
• Products or product candidates may be perceived as insufficiently effective, unsafe, or may result in unforeseen adverse events.
• Inability to comply with all FDA requests in a timely manner or at all.
• Inability to meet expectations with respect to sales of products or maintain profitability.
• Products may not be widely adopted by patients, payors, or healthcare providers, which would adversely impact the business.
• The estimates and judgments made, or the assumptions relied upon, in preparing financial statements could prove inaccurate.
• Inability to advance all programs, potentially leading to the pursuit of less profitable or successful programs.
• Success in clinical trials, especially if based on a small patient sample, does not ensure later clinical trial success or regulatory approval.
• Existing and any future indebtedness could adversely affect the ability to operate the business.
• Revenues and operating results could fluctuate significantly, which may adversely affect the stock price and business.
• Possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on the business.

Future Outlook

Sarepta reconfirmed its yearly sales floor for ELEVIDYS at $500.0 million and intends to exceed it, though detailed guidance will be withheld until evaluating results of 2026 initiatives. The company plans important initiatives in 2026 to continue the success of its approved therapies, particularly ELEVIDYS, and to advance its next-generation siRNA pipeline.

Management Comments

• "Sarepta faced and overcame challenges in 2025, achieving meaningful pipeline progress and solid performance."
• "In the face of obstacles, we achieved $1.86 billion in total net product revenue, and ELEVIDYS achieved $898.7 million."
• "At $110.4 million, ELEVIDYS fourth quarter revenue was impacted by the severe year-end flu season and the need in December to reschedule 6 patient infusions into 2026."
• "At $965.6 million in durable revenue, our PMO franchise continued to deliver for patients."
• "And importantly, we generated another quarter of positive cash flow and ended the year with $953.8 million in cash, cash equivalents, restricted cash and investments, giving us the financial strength to fully invest in our approved therapies and advance our next-generation siRNA pipeline."
• "We have important initiatives in 2026 to continue the success of our approved therapies, particularly ELEVIDYS."
• "We previously set a yearly sales floor for ELEVIDYS of $500.0 million. We reconfirm that floor and our intentions to exceed it."
• "However, we will stop short of providing more detailed guidance until we begin to evaluate the results of our initiatives."
• "We enter 2026 on a strong financial footing, with significant opportunities with our four approved therapies and our exciting siRNA pipeline."

Industry Context

This announcement provides an early look at Sarepta's performance in the competitive rare disease and gene therapy market, particularly for Duchenne muscular dystrophy. The strong full-year ELEVIDYS sales, significantly above the company's self-imposed floor, suggest a robust market reception for its gene therapy despite Q4 challenges. The focus on advancing the siRNA pipeline indicates continued investment in next-generation therapies, a common strategy among leading biotech firms to maintain a competitive edge and address unmet medical needs.

Stakeholder Impact

• Shareholders: Positive financial results and strong cash position could lead to increased investor confidence and potential share price appreciation. The reconfirmation of the ELEVIDYS sales floor and commitment to exceeding it provides positive guidance.
• Patients (DMD): Continued success and investment in ELEVIDYS and the siRNA pipeline offer hope for ongoing and future treatment options for Duchenne muscular dystrophy and other rare diseases. However, the detailed safety information for ELEVIDYS highlights significant risks that patients and healthcare providers must consider.
• Employees: Strong company performance and pipeline advancement suggest stability and continued investment in research and development.
• Healthcare Providers: The detailed safety information for ELEVIDYS provides critical guidance for prescribing and monitoring patients, emphasizing the need for careful patient selection and post-infusion management.

Next Steps

• Report final and complete fourth quarter and full-year 2025 financial results in late February 2026.
• Continue important initiatives in 2026 to ensure the success of approved therapies, especially ELEVIDYS.
• Advance the next-generation siRNA pipeline.

Key Dates

Recommendation

Sarepta Therapeutics has demonstrated strong financial performance for full-year 2025, with total net product revenue reaching $1.86 billion and ELEVIDYS sales significantly exceeding the company's own $500 million floor at $898.7 million. The company also reported a robust cash position of $953.8 million, indicating financial strength to invest in its pipeline and approved therapies. While Q4 ELEVIDYS revenue saw a minor impact from flu season and rescheduled infusions, this appears to be a temporary operational issue rather than a fundamental demand problem. The reconfirmation of the ELEVIDYS sales floor and commitment to exceeding it, coupled with ongoing pipeline advancements in siRNA, suggest continued growth potential. The detailed risk factors for ELEVIDYS are standard for gene therapies and are well-disclosed, not presenting new or unexpected concerns that would fundamentally alter the investment thesis. Given the strong revenue growth, healthy cash flow, and positive outlook for its key products and pipeline, a 'buy' recommendation is warranted for investors with an appropriate risk tolerance for biotechnology.

Keywords

Sarepta Therapeutics, SRPT, Duchenne muscular dystrophy, DMD, ELEVIDYS, gene therapy, PMO, net product revenue, financial results, biotechnology, rare diseases, J.P. Morgan Healthcare Conference